Jinxin Fertility Group Limited
錦欣生殖醫療集團有限公司*
(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 1951)

POSITIVE PROFIT ALERT
TURNAROUND FROM NET LOSS TO NET PROFIT

The announcement is made by Jinxin Fertility Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with the IFRS Accounting Standards as issued by the International Accounting Standards Board) for the six months ended June 30, 2026 ("**1H2026**"), it is expected that the Group will (i) achieve a turnaround of profitability from a net loss of approximately RMB1,044.1 million for the six months ended June 30, 2025 ("**1H2025**") into a profit for the period of not less than RMB90.0 million for 1H2026; (ii) record an earnings before interest, taxes, depreciation, and amortization ("**EBITDA**") (non-IFRS measure) of not less than RMB290 million, as compared to a negative EBITDA of approximately RMB938.2 million for 1H2025; (iii) record an adjusted earnings before interest, taxes, depreciation, and amortization (non-IFRS measure[1]) ("**Adjusted EBITDA**") of not less than RMB300.0 million, as compared to an Adjusted EBITDA of approximately RMB224.7 million for 1H2025; and (iv) record an adjusted net profit ("**Adjusted Net Profit**") of not less than RMB120.0 million, as compared to an adjusted net profit of approximately RMB82.3 million for 1H2025.

[1] Non-IFRS adjusted EBITDA is calculated as profit before taxation, plus finance costs (excluding interest on lease liabilities), depreciation of property, plant and equipment and amortization of medical practice license and non-compete agreement, less interest income for 1H2026, while non-IFRS adjusted net profit is calculated as the profit for 1H2026, in both cases excluding ESOP expenses. The Adjusted EBITDA and Adjusted Net Profit for 1H2025 were calculated on the same basis and included adjustments for the impairment losses and certain other one-off items recognized during that period, which were not applicable for 1H2026.

The increases in Adjusted EBITDA and Adjusted Net Profit were primarily attributable to: (i) the continued recovery of the Group's business in the United States, resulting in an increase in the number of oocyte pick up ("**OPU**") cycles; (ii) the Group's continued expansion of personalized services, which contributed to an increase in VIP client penetration; and (iii) the further promotion and wider adoption of assisted reproductive services in China, which drove an overall increase in the number of new patient visits for infertility. The Company's turnaround from net loss to net profit and from negative EBITDA and positive EBITDA was primarily attributable to the non-recurrence during the period of the significant impairment losses and other one-off items recognized in 1H2025.

The Company is still in the process of finalizing the interim results of the Group for 1H2026. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for 1H2026, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit and risk management committee of the Board. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for 1H2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

Hong Kong, July 21, 2026

As at the date of this announcement, the Board comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as chairman and non-executive Director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

* *For identification purposes only*